loading
전일 마감가:
$30.64
열려 있는:
$30.88
하루 거래량:
225.60K
Relative Volume:
0.43
시가총액:
$2.13B
수익:
-
순이익/손실:
$-179.27M
주가수익비율:
-12.04
EPS:
-2.56
순현금흐름:
$-155.88M
1주 성능:
+2.94%
1개월 성능:
-0.86%
6개월 성능:
+51.36%
1년 성능:
+90.63%
1일 변동 폭
Value
$29.97
$31.19
1주일 범위
Value
$27.05
$31.60
52주 변동 폭
Value
$15.32
$37.00

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name
명칭
Akero Therapeutics Inc
Name
전화
650-487-6488
Name
주소
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Name
직원
60
Name
트위터
@akerotx
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
AKRO's Discussions on Twitter

AKRO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
AKRO 30.70 2.13B 0 -179.27M -155.88M -2.56
VRTX 450.26 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.54 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 591.88 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 245.32 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.56 24.89B 3.30B -501.07M 1.03B 11.54

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-04-22 재개 BofA Securities Neutral
2023-09-19 개시 Cantor Fitzgerald Overweight
2023-08-28 개시 UBS Buy
2023-01-27 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-09-14 업그레이드 Evercore ISI In-line → Outperform
2021-10-19 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-09-10 개시 BofA Securities Buy
2021-02-26 개시 Guggenheim Buy
2020-09-10 개시 Morgan Stanley Overweight
2020-07-20 재확인 H.C. Wainwright Buy
2020-07-07 개시 Chardan Capital Markets Buy
2020-07-01 재확인 H.C. Wainwright Buy
2020-03-02 개시 H.C. Wainwright Buy
2020-02-10 개시 Canaccord Genuity Buy
2019-07-15 개시 Evercore ISI Outperform
2019-07-15 개시 JP Morgan Overweight
2019-07-15 개시 Jefferies Buy
2019-07-15 개시 ROTH Capital Buy
모두보기

Akero Therapeutics Inc 주식(AKRO)의 최신 뉴스

pulisher
06:04 AM

How To Trade (AKRO) - Stock Traders Daily

06:04 AM
pulisher
Nov 20, 2024

NASH Updates: Boston Pharma, Viking Line Up As Serious Competitors - Scrip

Nov 20, 2024
pulisher
Nov 19, 2024

Akero Therapeutics' chief development officer sells $251,274 in stock - Investing.com

Nov 19, 2024
pulisher
Nov 19, 2024

Citigroup Initiates Coverage of Akero Therapeutics (AKRO) with Buy Recommendation - MSN

Nov 19, 2024
pulisher
Nov 18, 2024

Inventiva Getting Back On Track In NASH Development - Citeline News & Insights

Nov 18, 2024
pulisher
Nov 18, 2024

Akero a new buy at Citi on liver disease asset - Seeking Alpha

Nov 18, 2024
pulisher
Nov 18, 2024

HC Wainwright Reaffirms "Buy" Rating for Akero Therapeutics (NASDAQ:AKRO) - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Citigroup Begins Coverage on Akero Therapeutics (NASDAQ:AKRO) - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Citi bullish on Akero stock as efruxifermin targets MASH market leadership - Investing.com Canada

Nov 18, 2024
pulisher
Nov 15, 2024

Akero Therapeutics (NASDAQ:AKRO) Shares Down 6.4%What's Next? - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Akero reports positive EFX trial results for liver disease By Investing.com - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

Akero reports positive EFX trial results for liver disease - Investing.com

Nov 15, 2024
pulisher
Nov 15, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Position Boosted by Simplify Asset Management Inc. - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Akero Therapeutics to Showcase New Analyses of Phase 2b - GlobeNewswire

Nov 15, 2024
pulisher
Nov 15, 2024

Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024 - Marketscreener.com

Nov 15, 2024
pulisher
Nov 15, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Large Decline in Short Interest - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Janus Henderson Group PLC's Strategic Acquisition of Akero Thera - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

What is HC Wainwright's Estimate for AKRO FY2024 Earnings? - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

RTW INVESTMENTS, LP Expands Stake in Akero Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Akero Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Akero Therapeutics to Present at Jefferies London Healthcare Conference | AKRO Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

ALKEON CAPITAL MANAGEMENT LLC Reduces Stake in Akero Therapeutics Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

FY2028 EPS Forecast for Akero Therapeutics Raised by Analyst - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Akero Therapeutics (NASDAQ:AKRO) Earns “Buy” Rating from HC Wainwright - Defense World

Nov 13, 2024
pulisher
Nov 12, 2024

Akero Therapeutics Advances in MASH Treatment Trials - Yahoo Finance

Nov 12, 2024
pulisher
Nov 11, 2024

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdateAkero Therapeutics, Inc. made significant strides in the third quarter of 2024, announcing the dosing of the first patient in the Phase 3 SYNCHRONY Outcomes study of i - Defense World

Nov 11, 2024
pulisher
Nov 10, 2024

(AKRO) Trading Advice - Stock Traders Daily

Nov 10, 2024
pulisher
Nov 09, 2024

Akero Therapeutics (NASDAQ:AKRO) Releases Earnings Results, Misses Estimates By $0.15 EPS - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Akero Therapeutics executive sells $351,890 in stock - Investing.com

Nov 08, 2024
pulisher
Nov 08, 2024

Akero Therapeutics executive sells $351,890 in stock By Investing.com - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

Wellington Management Group LLP's Strategic Acquisition of Akero Therapeutics Shares - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Akero Therapeutics Inc (AKRO) Quarterly 10-Q Report - Quartzy

Nov 08, 2024
pulisher
Nov 08, 2024

Akero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 08, 2024
pulisher
Nov 08, 2024

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 08, 2024
pulisher
Nov 08, 2024

Akero Reports $787M Cash Reserve, Advances Phase 3 MASH Drug Trials Despite Higher Costs | AKRO Stock News - StockTitan

Nov 08, 2024
pulisher
Nov 06, 2024

Analysts Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Price Target at $43.20 - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Akero Therapeutics COO sells $1.6 million in stock By Investing.com - Investing.com South Africa

Nov 05, 2024
pulisher
Nov 05, 2024

Akero Therapeutics COO sells $1.6 million in stock - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 50,716 Shares - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Akero Therapeutics CEO Andrew Cheng sells $3.4 million in stock By Investing.com - Investing.com Nigeria

Nov 05, 2024
pulisher
Nov 05, 2024

Akero Therapeutics CEO Andrew Cheng sells $3.4 million in stock - Investing.com

Nov 05, 2024
pulisher
Nov 04, 2024

abrdn plc Trims Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 4,515 Shares of Stock - MarketBeat

Nov 02, 2024
pulisher
Nov 02, 2024

Akero Therapeutics chief development officer sells $651,960 in stock - Investing.com India

Nov 02, 2024
pulisher
Nov 01, 2024

Akero Therapeutics chief development officer sells $651,960 in stock By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Oct 30, 2024

Axonis Therapeutics Announces $115 Million Series A Financing - Financial Times

Oct 30, 2024
pulisher
Oct 29, 2024

Akero Therapeutics (NASDAQ:AKRO) Trading Up 5.8%Here's What Happened - MarketBeat

Oct 29, 2024
pulisher
Oct 27, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Significant Decline in Short Interest - MarketBeat

Oct 27, 2024
pulisher
Oct 21, 2024

Akero Therapeutics to Present Data Reinforcing the Efficacy - GlobeNewswire

Oct 21, 2024
pulisher
Oct 21, 2024

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 - StockTitan

Oct 21, 2024
pulisher
Oct 20, 2024

Akero Therapeutics Insiders Sell US$1.2m Of Stock, Possibly Signalling Caution - Simply Wall St

Oct 20, 2024

Akero Therapeutics Inc (AKRO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
자본화:     |  볼륨(24시간):